logo

COVID-19: Drugs in Development

Share

The COVID-19 outbreak, which started in December 2019 in Wuhan City, China, was declared a "Public Health Emergency of International Concern" by the WHO on January 30, 2020. The outbreak was characterized as a pandemic on March 11, 2020.

Currently, there are no drugs to treat COVID-19, caused by the novel coronavirus SARS-CoV-2.

Listed below are companies that are in the race to find a treatment or vaccine for the novel coronavirus.

Subscribe to RTT Intelligent Investor for FREE 7-Day Trial with complete access to COVID-19 Drugs in Development Calendar.

Company Name
Drug
Current Stage
Next Milestone
Collaboration
Last Updated
Synairgen
SNG001
Positive data reported from the home cohort of SG016 Phase 2 study of SNG001 in Covid-19 patients. Also announced encouraging combined data for whole SG016 trial.
Data readout from the ongoing Phase 3 study in the second half of 2021.
-
04/30/2021
Bavarian Nordic A/S
ABNCoV2
Additional preclinical data showing the vaccine candidate's ability to induce neutralizing antibodies against SARS-CoV-2 variants, were reported.
Phase 2 study to start in the second quarter of 2021.
-
04/29/2021
Merck & Co Inc.
(MRK)
Molnupiravir
Merck signed voluntary licensing agreements with five Indian generics manufacturers including Cipla Limited, Dr. Reddy’s Laboratories Limited, Emcure Pharmaceuticals Limited, Hetero Labs Limited and Sun Pharmaceutical Industries Limited for its drug candidate Molnupiravir. Phase 3 study of Molnupiravir in non-hospitalized patients with confirmed Covid-19 is currently going on.
-
Ridgeback Biotherapeutics
04/28/2021
Kintor Pharmaceuticals
Proxalutamide
Initiated Phase 3 study of Proxalutamide in male patients with mild or moderate Covid-19 symptoms in the U.S.
-
-
04/27/2021
Medicago
Covid-19 vaccine candidate
The Interim Order (IO) rolling submission of Medicago's adjuvanted COVID-19 vaccine candidate has been accepted by Health Canada for review.
File last portion of the IO rolling submission after the Covid-19 vaccine efficacy and safety endpoint of the Phase 3 trial is reached.
-
04/26/2021
Verona Pharma plc
(VRNA)
Ensifentrine
The pilot study of a pressurized metered-dose inhaler (pMDI) formulation of ensifentrine showed that ensifentrine was well tolerated in patients hospitalized with Covid-19.
-
-
04/23/2021
Trevena, Inc.
(TRVN)
TRV027
TRV027 has been selcted to include in a Phase 2-Phase 3 trial as part of REMAP-CAP (Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia) in COVID-19 patients.
-
-
04/22/2021
Ocugen, Inc.
(OCGN)
COVAXIN
Second interim analysis of the Phase 3 study of Covaxin showed 78% efficacy after the second dose in preventing Covid-19; 100% in severe Covid-19; and 70% in asymptomatic Covid-19 infection.
-
Bharat Biotech
04/22/2021

Get Full Access to latest records of COVID-19 Drugs in Development Calendar by subscribing to RTT Intelligent Investor with FREE 7-Day Trial. (No Credit Card Required)

Editors Pick
Conagra Brands, Inc. (CAG) Thursday announced the appointment of Alexandre "Ale" Eboli as executive vice president and chief supply chain officer, effective August 2. Eboli has 25 years of experience in global end-to-end supply chain leadership in the consumer-packaged goods industry. Eboli will succeed... TJX Companies Inc. is recalling about 92,000 outdoor wooden folding chairs for potential risk of fall and injury hazards, a statement by the U.S. Consumer Product Safety Commission showed. The company said the chairs can break and can pose fall and injury hazards to the user. The company has received 18 reports of the recalled chairs breaking or collapsing, including 15 reports of falls. German automaker Volkswagen AG on Thursday raised its forecast for fiscal 2021 operating margin after reporting a significant growth in first-quarter profit with strong revenues and deliveries. The company also projects significantly higher revenues and deliveries in the full year. Meanwhile, Volkswagen shares were losing around 2 percent in German trading.